AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00803712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
Study NCT00803712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
Study NCT04074434 — intervention group
Intervention type: DEVICE
Intervention: Study Watch
Description: Study Watch is a miniaturized physiological data monitoring and data collection device for continuous recording of physiological and environmental data
Study NCT02259205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Yogurt
Description: 150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks
Study NCT02259205 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain Yogurt
Description: 150 g plain yogurt will be provided daily for 8 weeks
Study NCT03565874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: Before the start of the program and after one week of adherence to the program, two sessions will be conducted with a psychologist in order to define each participant's individual resonance frequency (i.e., breathing rhythm allowing for cardiac coherence), using the Nexus program from Mindmedia company. Then, each participant will receive training on the HRVB program using an Emwave device. The HRVB program itself will be carried individually for 20 min daily over the course of two weeks. Five daily sessions of 10 minutes will be considered as the minimum adherence to the program. Each participant will be asked to report in a diary all eventual major stressful life events.
Study NCT03417752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to firearm safety PSA
Description: Exposed to firearm safety PSA
Study NCT03417752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to health promotion PSA
Description: Exposed to general health promotion PSA
Study NCT03417752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to health promotion PSA
Description: Exposed to general health promotion PSA
Study NCT00874159 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire when entering the observational study.
Study NCT04512144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace Smartphone Application
Description: Headspace is a smartphone application used for mindfulness, meditation, and stress reduction. It has been utilized in other behavioral and quality of life studies.
Study NCT02806856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS neuroConn
Description: Cathodal on M1
Study NCT02806856 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham
Study NCT03701542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microperymetry
Description: Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
Study NCT03701542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: M-charts
Description: The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
Study NCT03180203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTELLiVENT-ASV
Description: After ICU admission:~* The first three hours: only ventilation with INTELLiVENT-ASV with Quickwean.~* After three hours: Automatic spontaneous breathing trials (SBT) is activated and SBT starts if >10minutes PEEP:\<9cmH2O,FiO2:\<41%,VT/IBW\<5ml/kg and RSB:\<106l/l\*min.~Settings SBT are MV% 25%,PEEP 5cmH2O.SBT automatically stops if respiratory rate >35b/min or increases >100% since start of SBT, FiO2 >50%, PeTCO2 increases >8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT >10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT.
Study NCT03180203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional modes
Description: After ICU admission:~The first three hours: only ventilation with CMV or PS. If required care providers may change the mode to adaptive support ventilation.~After three hours: manual SBT is required if >10min PS\<11cmH2O,PEEP\<9cmH2O,FiO2\<41%.~Settings SBT are PS 5cmH2O, PEEP 5cmH2O, FiO2 30%. SBT must be stopped if respiratory rate >35b/min or increases >100% since the start of SBT, saturation \<92% or the PeTCO2 increases >8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT >10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT.
Study NCT01952418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitor size
Description: Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor.
Study NCT00762762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/copolymer/fluoride
Description: Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
Study NCT00762762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
Study NCT02761590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training protocol
Description: The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.
Study NCT02761590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circuit training protocol
Description: The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.
Study NCT01562717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 3 times a day
Study NCT01562717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 times a day
Study NCT04423133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Family Literacy Program
Description: Parent-child dyads will participate in 8 weekly online health-themed workshops that introduce language and literacy skills. Participants will also receive 2-3 text messages per week for the duration of the program and children's books.
Study NCT00535431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AER 001
Description: 60 mg (in nebuliser), twice daily for 28 days
Study NCT00535431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sterile saline nebulised, twice daily for 28 days
Study NCT03170817 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Perfusion Rest/Stress Digital PET/CT
Description: Patients with coronary artery disease undergo a N-13 ammonia rest/stress PET/CT scan.~These patients are given:~1. One 5-10 mCI N13-ammonia (13N-NH3) intravenously and undergo a rest digital PET/CT scan of \~20 minute duration.~2. A dose of 0.4 mg regadenoson (Lexiscan) intravenously over 10 seconds to increase blood flow to the heart~3. One 5-10 mCi N13-ammonia (13N-NH3) intravenously and undergo a stress digital PET/CT scan of \~20 minute duration~Total patient time will take approximately up to 120 minutes.
Study NCT03170817 — intervention group
Intervention type: DRUG
Intervention: N-13 ammonia
Description: 5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress
Study NCT03170817 — intervention group
Intervention type: DRUG
Intervention: Regadenoson
Description: 0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
Study NCT01766531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: body bioelectrical impedance
Study NCT01672268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac computed tomography
Description: cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
Study NCT01672268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiac computed tomography
Description: cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
Study NCT02752438 — intervention group
Intervention type: DEVICE
Intervention: HFOV
Description: HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
Study NCT00941200 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood collection
Study NCT02210520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsatile ultrasound
Description: 1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
Study NCT02210520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous ultrasound
Description: 1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
Study NCT02210520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Description: 1 W/cm², 2 minutes in 6 points around the back spine
Study NCT04849663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: free fat graft
Description: fat harvested from patient will be used to cover exposed root
Study NCT04849663 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: subepithelial graft
Description: subepitheial graft harvested from palate
Study NCT02562586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Suction Drainage System
Description: patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
Study NCT02762435 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Description: light touch at established points on hand and wrist
Study NCT02762435 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no contact with the subject
Study NCT02762435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: moderate pressure at established points on hand and wrist
Study NCT01845597 — intervention group
Intervention type: PROCEDURE
Intervention: MAKOplasty® medial UKA
Description: A robot guided medial Unicompartmental knee arthroplasty (UKA) is a procedure to replace only the medial tibiofemoral compartment of the knee.
Study NCT01060423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Starting dose of 400mg/m2, followed by weekly 250mg/m2
Study NCT01060423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Starting dose of 400mg/m2, followed by weekly 250mg/m2
Study NCT01060423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² to be administered every two weeks
Study NCT01060423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irinotecan eluting BEADS
Description: A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
Study NCT04306497 — intervention group
Intervention type: DRUG
Intervention: TCM prescriptions
Description: TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
Study NCT03060226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample
Description: Search of blood predictive marker (s)
Study NCT03836157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: The dose will not be recalculated unless the patient has ±10% weight change.
Study NCT02297100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinumtoxin A
Description: 100 units of botox spread out among 10 separate injections
Study NCT03836157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.
Study NCT03639857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 532nm laser
Description: 532nm laser will be used to treat the lesion in this study arm.
Study NCT03639857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1064nm laser
Description: 1064nm laser will be used to treat the lesion in this study arm.
Study NCT03639857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: The topical corticosteroid will be used to treat the lesion in this study arm.
Study NCT03639857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroid
Description: The topical corticosteroid will be used to treat the lesion in this study arm.
Study NCT02981199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cell transplantation
Description: conditioning with chemotherapy \[VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)\], then stem cell transfusion
Study NCT03245320 — intervention group
Intervention type: DEVICE
Intervention: Integra TITAN™ Total Shoulder Generation 1.0
Description: Total Shoulder Arthroplasty or Hemiarthroplasty
Study NCT04398810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic single port cholecystectomy
Description: 1. Local anesthetic administration during wound incision In the experimental group and the control group, a local anesthetic was administered to the wound surface when a glove port was installed on the navel at the start of surgery. (bupivacaine 0.5% 14ml subcutaneous injection)~2. Residual gas aspiration~3. Pulmonary recruitment maneuver In both the experimental group and the control group, before the operation was completed and the wound was closed, the patient was taken to the Trenedelenburg position, and then the pressure of 60 cm H2o in the abdomen was applied, and manual inflation was performed twice, 5 seconds at a time, and pulmonary recruitment was performed.~4. Warming of the washing solution in the abdominal cavity
Study NCT02297100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injections upper aspect of trigone of urinary bladder
Description: We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
Study NCT02364297 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Early TIPS
Description: TIPS (first 5 days)
Study NCT02364297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Early TIPS
Description: TIPS (first 5 days)
Study NCT02297100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injections on posterior bladder wall excluding the trigone
Description: We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
Study NCT01025284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously as a 1-hour infusion
Study NCT01025284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Administered subcutaneously
Study NCT01587105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Case Management Service
Description: When a child enrolls in the CCM program, the child's parent will work together with the CCM team at Seattle Children's to develop a shared care plan for their child. This plan will include all of the child's routine health care needs and information about what to do when the child gets sick. The parent will also have 24 hour access to an on-call CCM nurse.
Study NCT02968108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects \<40 kg or 130 mg for subjects >= 40 kg in Group 1 and 9 mg/kg for subjects \< 40 kg or 390 mg for subjects >= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects \< 40 kg or 90 mg for subjects >= 40 kg at Week 8.
Study NCT01563328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: 50 mg q24h
Study NCT01563328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCV
Description: 800 mg q8h
Study NCT01563328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVR
Description: 750 mg q8h
Study NCT02767778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REAL Pulsed ELF-MF stimulation
Description: Within 48 hours from the onset of the stroke, the enrolled patients will undergo to 120 min, daily, pulsed ELF-MF treatment for 5 consecutive days, during their hospital stay.Pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy) producing a single-pulsed signal at 75±2 Hz, with a pulse duration of 1.3 ms and a peak intensity of the magnetic field of 1.8±0.2 mT.
Study NCT02767778 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Pulsed ELF-MF stimulation
Description: SHAM pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy). The device for SHAM stimulation is identical and produces the same auditory sensation of the device for REAL stimulation but the SHAM device has no stimulating effect on the brain.
Study NCT03793647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical muscle devise
Description: evaluate two types of EMS stimulation of legs
Study NCT03793647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical muscle devise
Description: evaluate two types of EMS stimulation of legs
Study NCT03793647 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical muscle devise
Description: evaluate two types of EMS stimulation of legs
Study NCT01534117 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelets
Description: 1 unit of platelets
Study NCT01534117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDAVP
Description: Desmopressin 0.3mcg/kg IV x 1
Study NCT03204617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM)
Description: Vaccine DNA.HTI 0.5mL at weeks 0, 4 and 8 + Vaccine MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM).
Study NCT03204617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)
Description: At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
Study NCT03204617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
Study NCT00798941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mouth care
Description: mouth spray, mouth swab, moisturizer
Study NCT00798941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain intervention
Description: music and massage
Study NCT02224612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medline Pediatric Face Masks
Description: Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
Study NCT02224612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KC Childs Mask
Description: KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
Study NCT01520207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol (20%)
Description: 0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)